Ouyang Zhaohui, Wei Ke
Institute for Regenerative Medicine, Shanghai East Hospital, Shanghai Institute of Stem Cell Research and Clinical Translation, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, P.R. China.
Cell Regen. 2021 Jun 1;10(1):14. doi: 10.1186/s13619-021-00077-5.
Ischemic heart disease is one of the main causes of morbidity and mortality in the world. In adult mammalian hearts, most cardiomyocytes are terminally differentiated and have extremely limited capacity of proliferation, making it impossible to regenerate the heart after injuries such as myocardial infarction. MicroRNAs (miRNAs), a class of non-coding single-stranded RNA, which are involved in mRNA silencing and the regulation of post-transcriptional gene expression, have been shown to play a crucial role in cardiac development and cardiomyocyte proliferation. Muscle specific miRNAs such as miR-1 are key regulators of cardiomyocyte maturation and growth, while miR-199-3p and other miRNAs display potent activity to induce proliferation of cardiomyocytes. Given their small size and relative pleiotropic effects, miRNAs have gained significant attraction as promising therapeutic targets or tools in cardiac regeneration. Increasing number of studies demonstrated that overexpression or inhibition of specific miRNAs could induce cardiomyocyte proliferation and cardiac regeneration. Some common targets of pro-proliferation miRNAs, such as the Hippo-Yap signaling pathway, were identified in multiple species, highlighting the power of miRNAs as probes to dissect core regulators of biological processes. A number of miRNAs have been shown to improve heart function after myocardial infarction in mice, and one trial in swine also demonstrated promising outcomes. However, technical difficulties, especially in delivery methods, and adverse effects, such as uncontrolled proliferation, remain. In this review, we summarize the recent progress in miRNA research in cardiac development and regeneration, examine the mechanisms of miRNA regulating cardiomyocyte proliferation, and discuss its potential as a new strategy for cardiac regeneration therapy.
缺血性心脏病是全球发病和死亡的主要原因之一。在成年哺乳动物心脏中,大多数心肌细胞已终末分化,增殖能力极其有限,这使得心肌梗死后心脏无法再生。微小RNA(miRNA)是一类非编码单链RNA,参与mRNA沉默和转录后基因表达调控,已被证明在心脏发育和心肌细胞增殖中起关键作用。肌肉特异性miRNA如miR-1是心肌细胞成熟和生长的关键调节因子,而miR-199-3p等其他miRNA则具有诱导心肌细胞增殖的强大活性。鉴于其体积小和相对多效性作用,miRNA作为心脏再生中有前景的治疗靶点或工具已备受关注。越来越多的研究表明,过表达或抑制特定miRNA可诱导心肌细胞增殖和心脏再生。在多个物种中鉴定出了一些促增殖miRNA的常见靶点,如Hippo-Yap信号通路,这突出了miRNA作为剖析生物过程核心调节因子探针的作用。已证明一些miRNA可改善小鼠心肌梗死后的心功能,一项在猪身上的试验也显示出了有前景的结果。然而,技术难题,尤其是在递送方法方面,以及诸如不受控制的增殖等不良反应仍然存在。在本综述中,我们总结了miRNA在心脏发育和再生研究中的最新进展,研究了miRNA调节心肌细胞增殖的机制,并讨论了其作为心脏再生治疗新策略的潜力。